Sign In
Free Newsletter
Novo Nordisk teams with OpenAI to speed drug development
Novo Nordisk and OpenAI partner to use AI for drug development, aiming to speed discovery, improve manufacturing and boost efficiency.
Novo Nordisk launches Wegovy subscription plan with savings
The new option offers lower monthly pricing for self-pay patients via telehealth platforms, such as Weight Watchers, LifeMD, Hims & Hers and Sesame, to expand access to GLP-1 weigh loss drugs.
Novo Nordisk, Hims & Hers settle GLP-1 drug dispute
The settlement between Novo Nordisk and Hims & Hers allows the telehealth platform to sell FDA-approved Wegovy and Ozempic GLP-1 drugs.
ShopRite launches GLP-1 wellness starter kits
Customers filling their first prescription will receive product samples, nutrition guides and recipes to support patients beginning weight loss medications.
Novo Nordisk’s Wegovy weight loss pill hits US market
The pharma launched a once-daily alternative to its injections, available nationwide after FDA approval at 70,000 pharmacies with starting doses priced at $149 per month.
FDA approves Wegovy weight loss pill from Novo Nordisk
The first oral GLP-1 obesity drug will launch in the U.S. at a $149 starting price in 2026.
Novo Nordisk, Eli Lilly cut GLP-1 drug costs under Medicare
The deals with the Trump administration will lower prices for weight loss and diabetes medications to make them more affordable for patients.
Novo Nordisk to cut 9,000 jobs in global restructuring
The moves aim to save $1.3 billion annually by next year, streamline operations and increase focus on diabetes and obesity growth.
Novo Nordisk ends Hims & Hers deal over Wegovy knockoffs
The conclusion of the collaboration comes as the drug maker cites illegal sales of compounded knockoff weight loss drugs and expresses growing concerns over patient safety.
Novo Nordisk expands Wegovy access as FDA bans semaglutide copies
The Swiss drugmaker – which has its U.S. headquarters in Plainsboro – is launching a series of initiatives to offer patients authentic versions of its blockbuster weight-loss treatment.
Frier Levitt to host webinar on GLP-1 legal risks
The boutique health care firm will host a May 15 event exploring compounding, legal risks, FDA regulations and the growing role of payers in obesity treatment.
Novo Nordisk seeks FDA approval for Wegovy weight loss pill
If the administration signs off on the application, the company’s experimental once-daily version will become the first oral GLP-1 for weight loss.
